Renovaro Inc (RENB)
1.59
+0.17
(+11.97%)
USD |
NASDAQ |
May 28, 11:42
Renovaro Enterprise Value: 216.26M for May 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 24, 2024 | 216.26M |
| May 23, 2024 | 201.51M |
| May 22, 2024 | 145.46M |
| May 21, 2024 | 148.41M |
| May 20, 2024 | 149.89M |
| May 17, 2024 | 149.89M |
| May 16, 2024 | 142.11M |
| May 15, 2024 | 146.54M |
| May 14, 2024 | 160.21M |
| May 13, 2024 | 177.91M |
| May 10, 2024 | 173.49M |
| May 09, 2024 | 183.79M |
| May 08, 2024 | 222.14M |
| May 07, 2024 | 226.56M |
| May 06, 2024 | 225.09M |
| May 03, 2024 | 228.04M |
| May 02, 2024 | 226.56M |
| May 01, 2024 | 223.61M |
| April 30, 2024 | 239.84M |
| April 29, 2024 | 236.89M |
| April 26, 2024 | 232.46M |
| April 25, 2024 | 257.54M |
| April 24, 2024 | 297.36M |
| April 23, 2024 | 304.73M |
| April 22, 2024 | 323.91M |
| Date | Value |
|---|---|
| April 19, 2024 | 326.86M |
| April 18, 2024 | 346.03M |
| April 17, 2024 | 334.23M |
| April 16, 2024 | 363.73M |
| April 15, 2024 | 368.15M |
| April 12, 2024 | 354.88M |
| April 11, 2024 | 368.15M |
| April 10, 2024 | 372.58M |
| April 09, 2024 | 418.30M |
| April 08, 2024 | 427.15M |
| April 05, 2024 | 413.88M |
| April 04, 2024 | 418.30M |
| April 03, 2024 | 415.35M |
| April 02, 2024 | 422.72M |
| April 01, 2024 | 449.27M |
| March 28, 2024 | 386.99M |
| March 27, 2024 | 407.10M |
| March 26, 2024 | 425.78M |
| March 25, 2024 | 424.34M |
| March 22, 2024 | 470.31M |
| March 21, 2024 | 428.65M |
| March 20, 2024 | 424.34M |
| March 19, 2024 | 466.00M |
| March 18, 2024 | 437.27M |
| March 15, 2024 | 461.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
28.53M
Minimum
Jun 28 2023
645.83M
Maximum
Nov 30 2021
208.60M
Average
186.33M
Median
Jul 23 2020
Enterprise Value Benchmarks
| DIH Holding US Inc | -- |
| AIM ImmunoTech Inc | 12.06M |
| Perspective Therapeutics Inc | 755.01M |
| Protalix BioTherapeutics Inc | 62.11M |
| Armata Pharmaceuticals Inc | 188.90M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.02M |
| Total Expenses (Quarterly) | 8.770M |
| EPS Diluted (Quarterly) | -0.16 |
| Earnings Yield | -49.06% |